3. Continue Reading for Our Disclosure... Terrence W. Norchi—MD, MBA, President, CEO, and Chairman Terrence W. Norchi, MD, our co-founder, serves as our President and Chief Executive Officer, and he is a director on our Board of Directors. Dr. Norchi has served in similar positions since co- founding Arch Therapeutics. Prior to Arch, Dr. Norchi was portfolio manager of one of the world’s largest healthcare mutual funds and pharmaceutical analyst at Putnam Investments. Prior to that he served as the senior global biotech and international pharmaceutical equity analyst at Citigroup Asset Management, and as a sell-side analyst covering non-U.S. pharmaceutical equities at Sanford C. Bernstein in New York City. Daniel C. Wadsworth, Jr.—VP of Dermal Sciences Mr. Wadsworth, an advisor to Arch as of 2019, has more than 30 years of experience leading innovation in scientific and engineering enterprises and driving value in public and private life science companies. He has commercialized over 100 medical device technology advancements in fields including wound healing, cancer drug delivery, ESRD, atherosclerotic disease, and orthopedics. Mr. Wadsworth has held executive leadership roles in medical device companies such as CR Bard (BD) and KCI (Acelity), and he has had responsibility for Commercialization, Research and Development, Quality and Regulatory organizations. He is also an entrepreneur, co-founder and COO of Metric Medical Devices, Inc. and is the recipient of two US patents in chemotherapy drug delivery. Mr. Wadsworth has a BS in Biology from the University of New York at Albany and a Masters in Biomedical Engineering from Worcester Polytechnic Institute. John Richards John Richards, DPhil., who started advising Arch Therapeutics in 2016, brings over 30 years of pharmaceutical industry and peptide chemistry experience. Since 2009, he has been Vice President of Global Pharmaceutical Development at The Medicines Company, responsible for CMC development and manufacturing of all the company’s products, including the very large scale program for the peptide-based anticoagulant, Angiomax®. He has extensive experience leading CMC programs which have resulted in the successful filing and approval of drugs and biologics in the United States, European Union and other territories. Management
4. "Full Market Awareness" A professional relations company and consulting firm Contact: Sean McDonald smcdonald@acornmanagementpartners.com 941 . 208.3919 Atlanta,Georgia & Sarasota,Florida Disclaimer Notice: The information contained in this e-mail message and its attachments is intended solely for the use of the individual(s) to whom it is addressed and may contain information that is the confidential information of Acorn Management Partners L.L.C. ("AMP") and its subsidiaries. The Information may be about companies in which A.M.P has or may receive compensation in the future. Any material in this message should be considered as ADVERTIS E MENT ONLY. Please consult with a certified financial advisor before making any investment decisions. All information on this report should be confirmed before making an investment decision. Acorn Management Partners L.L.C. ("AMP") and its subsidiaries, and any affiliates and information providers make no implied or express warranties on the information provided. This is not to be construed as a solicitation to buy or sell securities. As with any stock, the featured companies involve a high degree of risk and volatility, and all investors/advisors should know that they may lose a portion or all of their investment if they decide to purchase any stock. Acorn Management Partners L.L.C. ("AMP"), its affiliates, associates, relatives and anyone associated with in any manner reserves the right to either buy or sell shares in the profiled company's stock. The Securities and Exchange Commission has compiled an extensive amount of information concerning investing, including the inherent risks involved. We encourage our readers to visit the SEC's website to acquire this important information. Safe Harbor Dis- closure: Acorn Management Partners L.L.C. ("AMP") website publications may contain or incorporate by reference "forward- looking statements, including certain information with respect to plans and strategies of the featured company. As such, any statements contained herein or incorporated herein by reference that are not statements of historical fact may be deemed to be forward- looking statements. Without limiting the forgoing, the words "believe(s)," "anticipate(s)," "plan(s)," "expect(s)," "project(s)" and similar expressions are intended to identify forward-looking statements. There are a number of important factors that could cause actual events or actual results of the Companies profiled herein to differ materially from these indicated by such forward-looking statements. Certain statements contained herein constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and 21E of the Exchange Act of 1934. Such statements include, without limitation, statements regarding business and financing, business trends, future operating revenues and expenses. Although the Company believes that the statements are reasonable, it can give no assurances that such expectations will prove to be correct. Investors are cautioned that any forward-looking statements made by the Company or contained in any and/or all profile/ research reports, contain no guarantee of future performance, and that the actual result may differ materially from those set forth in the forward-looking statements. Difference in results can be caused by various fa ctors including, but not limited to, the Company's ability to be able to successfully complete planned funding agreements, to successfully market its products in competitive industries or to effectively implement its business plan or strategies. Any statements that express or involve discussions with respect to predictions, expectat ions, beliefs, plans, projections, objectives, goals, assumptions, or future events or performance are not statements of historical fact and may be "forward looking statements." Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking stat ements in this action may be identified through the use of words such as "expects," "will," "anticipates," "estimates," "believes," "may," or by statements indicating certain actions "may," "could," or "might" occur. We encourage our readers to invest carefully and review all forms of investments and read the investor information. More information please visit http:// www.sec.gov and/or (FINRA) at: http://www.FINRA.com. Readers can review all public filings by compan ies at the SEC's EDGAR page. The FINRA has published information on how to invest carefully at its web s ite.
2. Continue Reading for Management Background and Our Disclosure... Arch boast’s a broad IP portfolio consisting of an e xclusive license from MIT for two patent families that c over composition and methods for hemostasis and controlling movement of bodily substances with expected expiry from 2026-2028 . Arch Therapeutics is the sole licensee worldwide of these 2 exclusive licenses. Arch also has a non-exclusive licensing agreement from MIT for 5 patent families providing freedom t o operate. The Company also has their own intellectual property covering ‘ treatment of damaged tight junction and enhance extracellular matrix and compositions for prevention of adhesion and other barrier applicati ons .’ Intellectual Property Projected Market The global Hemostats market was valued at 2,587.34 Million USD in 2020 and will grow with a CAGR of 17.75% from 2020 to 2027 . Unlike many competitive products, it conforms to irregular wound geometry , allows for normal healing, helps maintain a clear field of vision , and, as shown, acts quicker than competing hemostats and anticoagulants. Target Markets: Surgery: Arch Therapeutics plans to focus on surgery markets first, where its superior technology and cost - competitiveness should translate into a quick and large market penetration. Trauma: The next likely focus of the Company’s marketing efforts, the trauma market is very large and consists of civilian and military first-responders. Home Use: At some point, the product’s low manufacturing cost and ease of use should allow it to compete in the home-use market, both domestically and abroad Chronic Wounds: pressure ulcers, diabetic foot ulcers, GI Sealants, ophthalmology application, burns. Commercial Efforts: • Arch has started a 6 - month pilot program that will help them attain insurance reimbursement for Medicare/ Medicaid and other private insurance payers. • The Arch internal team now has: o a national sales director o 2 regional directors o 12-14 other sales members that are commercializing the first product, AC5 Advanced Wound System in the US.
1. AMP Quick Facts Arch Therapeutics Inc. ( OTC : ARTH ) November 2021 Nasdaq: ARTH Price: $0.11 Date: 10/27/2021 Fiscal Year: 12/31 MKT Cap: ~ $25.01 M C.O.H*: ~ 3.8 M Institutional Ownership: ~ .03 % Inside Ownership: ~ 13.51 % S/O*: ~ 236.7 M Float: ~ 204.7 M AVG Vol.: ~ 650 K For More Information Please Call: Brandon Bouysou 678.736.5686 Industry: " Biotechnology & Hemostat & Wound Care " Continue Reading for More Information, Recent News, Management Background & Our Disclosure... https://www.archtherapeutics.com/ Arch Therapeutics, Inc. (OTCQB: ARTH) is a Boston-based life sciences company that develops products to stop bleeding and control leaking during surgery and trauma care . Both bleeding and leaking are big problems for first responders and surgeons around the world , and if not well-controlled are major drivers of poor surgical outcomes , including: patient mortality . Both Arch and independent investigators reported results in animal liver surgery that supported AC5™ promptly stopped bleeding in animals that were on the anticoagulant heparin with a time-to-hemostats (TTH) that was equivalent to the TTH of those animals and confirmed in humans not on blood thinners, representing a major differentiating feature with implications for surgery , home care and trauma. Arch Therapeutics is developing the AC5 Surgical Hemostat Device™, to work better and with fewer side effects , and be very easy to prepare and apply . Watch: Arch Therapeutics Self-Assembling Peptide (SAP) Technology Making it especially valuable in time-critical in surgical and trauma applications. Company Highlights: • Arch Therapeutics Partners with Lovell Government Services to Expand Distribution Capabilities • Arch's AC5® Advanced Wound System presents with recognition at the 2021 Symposium on advanced wound care. • Arch Received CE Mark Approval for AC5™ Topical Hemostat in Europe • Arch Received 510(k) Clearance from FDA for AC5® Advanced Wound System (Less than 5% of R&D biotech companies ever make it to the approval stage) • Arch Therapeutics Receives Marketing Clearance from the US FDA Related to the AC5® Advanced Wound System • ARTH is looking to be the Gold Standard (New standard of care) across multiple wound care indications Acorn Management Partners, LLC
